Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Treatment of Chronic Hepatitis B

Publication Date: January 1, 2016

Last Updated: March 14, 2022

Recommendations

Treatment of Persons With Immune-Active CHB

The AASLD recommends antiviral therapy for adults with immune-active CHB (HBeAg negative or HBeAg positive) to decrease the risk of liver-related complications. (SM)

322286

The AASLD recommends Peg-IFN, entecavir, or tenofovir as preferred initial therapy for adults with immune-active CHB. (SL)

Treatment of Chronic Hepatitis B

Recommendations

Treatment of Persons With Immune-Active CHB

Overview

Title

Authoring Organization